Alzheimer’s disease patients carrying a gene found only in humans, called CHRFAM7A, are less responsive to cholinesterase inhibitors, a new study reports. These findings may explain why some therapeutic benefits seen in animal studies have failed to translate to patients.
“This research provides proof of concept that since different mechanisms are at work in Alzheimer’s in different patients, we need to develop more personalized treatments that will prove more effective in individuals,” said Szigeti, who is also an associate professor of neurology in the Jacobs School of Medicine and Biomedical Sciences at UB.
